# OnCo record senti-biosciences (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/senti-biosciences/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "senti-biosciences" ;
  schema:name "Senti Biosciences"@en ;
  schema:alternateName "Senti Bio"@en, "Senti Biosciences Holdings, Inc."@en ;
  schema:description "Senti Bio builds programmable 'gene circuits' into immune cells so they can tell cancer cells from healthy ones. Its lead product, SENTI-202, is an off-the-shelf CAR-NK cell therapy, made from donor natural killer cells, for acute myeloid leukaemia."@en ;
  schema:url <https://onco.cc/companies/senti-biosciences/>, <https://www.sentibio.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.sentibio.com/>, <https://www.sentibio.com/research-pipeline/senti-202/>, <https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001854270>, <https://clinicaltrials.gov/study/NCT06325748> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/mds/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/logic-gated-therapeutics/>, <https://onco.cc/technologies/nk-cell-therapy/>, <https://onco.cc/technologies/allogeneic-cell-therapy/> ;
  onco:targets <https://onco.cc/targets/cd33/>, <https://onco.cc/targets/flt3/> .